-
Mashup Score: 9Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia - 7 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 12023 ASH AML Updates [Slides] - Kiran Naqvi MD - MOASC - 8 month(s) ago
2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abs…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3 - 1 year(s) ago
Results of the TIVO-3 trial suggested that tivozanib has a progression-free survival advantage compared with sorafenib; however, it has been speculated that pri
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results of the TIVO-3 trial suggested that #tivozanib has a PFS advantage over #sorafenib; however, prior use of #axitinib may render tivozanib less effective. This article examines the TIVO-3 dataset for outcomes of patients with prior axitinib therapy. https://t.co/W4LMwf2lcx https://t.co/4AujJnhQYc
-
-
Mashup Score: 0Radiation + Sorafenib Extends Survival for HCC - 1 year(s) ago
Study also suggests improved quality of life for patients who received the combination of therapies versus the TKI alone.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1SBRT Plus Sorafenib Improves Survival in Locally Advanced HCC - 1 year(s) ago
In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
👉👉👉Brand new paper alert 🚨 from our group ➡️ Ph2 CLIA w/ or w/out #sorafenib for upfront AML therapy || https://t.co/rsoizh9gbS || led by @TapKadia & @DrHKantarjian @MDAndersonNews #leusm #endcancer | @GBorthakur @Daver_Leukemia @doctorpemm @NitinJainMD @MusaYilmazMD https://t.co/uL55p0mftM